BMS gets FDA nod for Opdivo as first adjuvant bladder cancer therapyBristol Myers Squibb has scored a win in its drive to get Opdivo into earlier lines of cancer Share XBMS gets FDA nod for Opdivo as first adjuvant bladder cancer therapyhttps://pharmaphorum.com/news/bms-gets-fda-nod-for-opdivo-as-first-adjuvant-bladder-cancer-therapy/
GSK claims broader ’tissue-agnostic’ label for PD-1 drug JemperliThe FDA has approved GlaxoSmithKline’s latecomer PD-1 inhibitor Jemperli for a second use that will significantly extend the Share XGSK claims broader ’tissue-agnostic’ label for PD-1 drug Jemperlihttps://pharmaphorum.com/news/gsk-claims-broader-tissue-agnostic-label-for-pd-1-drug-jemperli/
FDA starts speedy review of Keytruda for adjuvant kidney cancerMerck & Co is looking at a decision from the FDA in December on its application to market Share XFDA starts speedy review of Keytruda for adjuvant kidney cancerhttps://pharmaphorum.com/news/fda-starts-speedy-review-of-keytruda-for-adjuvant-kidney-cancer/
Sanofi and Regeneron eye Libtayo challenge to Keytruda in first-line lung cancerSanofi and Regeneron’s latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche Share XSanofi and Regeneron eye Libtayo challenge to Keytruda in first-line lung cancerhttps://pharmaphorum.com/news/sanofi-regeneron-eye-libtayo-challenge-to-merck-in-first-line-lung-cancer/
Roche gets fast FDA review for Tecentriq in adjuvant lung cancerRoche is preparing for a December verdict from the FDA on adjuvant use of its PD-L1 inhibitor Tecentriq Share XRoche gets fast FDA review for Tecentriq in adjuvant lung cancerhttps://pharmaphorum.com/news/roche-gets-fast-fda-review-for-tecentriq-in-adjuvant-lung-cancer/
After false start, Merck claims Keytruda approval in early breast cancerMerck & Co’s Keytruda has just picked up its 30th approval from the FDA, and it is a Share XAfter false start, Merck claims Keytruda approval in early breast cancerhttps://pharmaphorum.com/news/after-false-start-merck-claims-keytruda-approval-in-early-breast-cancer/
BMS pulls speedy Opdivo approval for liver cancer in USBristol-Myers Squibb has withdrawn its US marketing approval for PD-1 inhibitor Opdivo as a second-line, single-agent treatment for Share XBMS pulls speedy Opdivo approval for liver cancer in UShttps://pharmaphorum.com/news/bms-pulls-speedy-opdivo-approval-in-liver-cancer-in-us/
Merck pulls Keytruda’s FDA nod for third-line stomach cancerMerck & Co will voluntarily withdraw a US marketing approval for cancer immunotherapy blockbuster Keytruda in gastric cancer, Share XMerck pulls Keytruda’s FDA nod for third-line stomach cancerhttps://pharmaphorum.com/news/merck-pulls-keytrudas-fda-nod-for-third-line-stomach-cancer/
Keytruda beats Opdivo to first-line oesophageal cancer OK in EuropeMerck & Co’s Keytruda has become the first cancer immunotherapy to be approved as a first-line oesophageal cancer Share XKeytruda beats Opdivo to first-line oesophageal cancer OK in Europehttps://pharmaphorum.com/news/keytruda-beats-opdivo-to-first-line-oesophageal-cancer-ok-in-europe/
